Advertisement

Outcomes of Patients With Cancer Who Underwent Transcatheter Mitral Valve Repair With MitraClip

      Mitral regurgitation (MR) is the most prevalent valvular heart disease, and the condition portends considerable public health implications. Multiple treatment modalities have emerged in recent years, including the use of transcatheter mitral valve repair (TMVr), for select patient populations with moderate to severe MR. In particular, the MitraClip TMVr system has been proposed as an alternative to surgical mitral valve procedures in inoperable patients with degenerative MR or in those with severe symptomatic functional MR because of reduced ejection fraction or left atrial dilation despite guideline-directed medical therapy.
      • Stone GW
      • Lindenfeld J
      • Abraham WT
      • Kar S
      • Lim DS
      • Mishell JM
      • Whisenant B
      • Grayburn PA
      • Rinaldi M
      • Kapadia SR
      • Rajagopal V
      • Sarembock IJ
      • Brieke A
      • Marx SO
      • Cohen DJ
      • Weissman NJ
      • Mack MJ
      • Investigators COAPT
      Transcatheter mitral-valve repair in patients with heart failure.
      Although previous studies have described the use of transcatheter aortic valve replacement in patients with malignancy,
      • Lind A
      • Totzeck M
      • Mahabadi AA
      • Jánosi RA
      • El Gabry M
      • Ruhparwar A
      • Mrotzek SM
      • Hinrichs L
      • Akdeniz M
      • Rassaf T
      • Mincu RI.
      Impact of cancer in patients undergoing transcatheter aortic valve replacement: a single-center study.
      there is a paucity of data investigating outcomes of TMVr in patients with a history of cancer. Several factors may contribute to an untoward prognosis after TMVr in patients with malignancy, including a chronic inflammatory state, consequent frailty, and risks associated with previous treatment with surgery, chemotherapy, and/or radiation. As such, it is not known whether TMVr would be as useful a treatment in the cancer population. Accordingly, using a large nationwide sample, we sought to compare the clinical characteristics and short-term outcomes of patients who underwent MitraClip with and without a history of malignancy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stone GW
        • Lindenfeld J
        • Abraham WT
        • Kar S
        • Lim DS
        • Mishell JM
        • Whisenant B
        • Grayburn PA
        • Rinaldi M
        • Kapadia SR
        • Rajagopal V
        • Sarembock IJ
        • Brieke A
        • Marx SO
        • Cohen DJ
        • Weissman NJ
        • Mack MJ
        • Investigators COAPT
        Transcatheter mitral-valve repair in patients with heart failure.
        N Engl J Med. 2018; 379: 2307-2318
        • Lind A
        • Totzeck M
        • Mahabadi AA
        • Jánosi RA
        • El Gabry M
        • Ruhparwar A
        • Mrotzek SM
        • Hinrichs L
        • Akdeniz M
        • Rassaf T
        • Mincu RI.
        Impact of cancer in patients undergoing transcatheter aortic valve replacement: a single-center study.
        JACC Cardiooncol. 2020; 2: 735-743
        • Tabata N
        • Weber M
        • Sugiura A
        • Öztürk C
        • Tsujita K
        • Nickenig G
        • Sinning JM.
        Impact of cancer history on clinical outcome in patients undergoing transcatheter edge-to-edge mitral repair.
        Clin Res Cardiol. 2021; 110: 440-450
        • Pibarot P
        • Delgado V
        • vs Bax JJ.MITRA FR
        COAPT: lessons from two trials with diametrically opposed results.
        Eur Heart J Cardiovasc Imaging. 2019; 20: 620-624
        • Otto CM
        • Nishimura RA
        • Bonow RO
        • Carabello BA
        • Erwin 3rd, JP
        • Gentile F
        • Jneid H
        • Krieger EV
        • Mack M
        • McLeod C
        • O'Gara PT
        • Rigolin VH
        • Sundt 3rd, TM
        • Thompson A
        • Toly C
        2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines.
        Circulation. 2021; 143: e35-e71